Benitec Biopharma (BNTC)
NASDAQ:BNTC
Want to see BNTC full AI Analyst Report?
BNTC Stock Chart & Stats
$14.08
<$0.01(0.09%)
At close: 4:00 PM EST
$14.08
<$0.01(0.09%)
Day’s Range― - ―
52-Week Range$9.85 - $17.10
Previous CloseN/A
Volume10.71K
Average Volume (3M)87.67K
Market Cap
$384.08M
Enterprise Value$119.53M
Total Cash (Recent Filing)$184.76M
Total Debt (Recent Filing)$876.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 30, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding34,354,336
10 Day Avg. Volume85,008
30 Day Avg. Volume87,665
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)4.35
Price to Sales (P/S)0.00
P/FCF Ratio-17.95
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-251.64
Enterprise Value/Ebitda-2.24
Forecast
1Y Price Target
$25.00Price Target Upside77.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary DdRNAi PlatformBenitec’s ddRNAi platform is a proprietary gene‑silencing technology engineered for long‑lasting suppression of disease genes. A platform approach can generate multiple pipeline candidates and licensing opportunities, creating a durable competitive moat if clinical translation and regulatory approvals progress.
Low Leverage Balance SheetVery low debt relative to equity and sizable assets reduce refinancing and solvency risk, giving management flexibility to fund R&D or pursue partnerships. This conservative capital structure provides a durable cushion vs peers and supports strategic options over the medium term.
Board Refresh / GovernanceA governance refresh and addition of an independent director represent a structural leadership change. Stronger board oversight can improve capital allocation, partner sourcing and strategic discipline, which materially affects long‑term execution and shareholder alignment.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates ongoing cash consumption to fund operations. This creates a durable dependence on external financing or partnerships, increases dilution risk, and can constrain program timelines and investment in the pipeline absent material funding events.
Minimal Commercial RevenueEssentially pre‑commercial status with trivial revenue leaves the business unable to self‑fund growth. Over the medium term this amplifies execution risk: progress depends on clinical milestones, licensing deals or capital raises rather than sustainable product cash flows.
Negative Returns Eroding EquityA deeply negative ROE shows operating losses are consuming equity value. Persistently negative returns can degrade the balance sheet, limit strategic flexibility, and reduce investor confidence unless clinical progress reverses the trend toward profitability or transformative value creation.
Benitec Biopharma News
BNTC FAQ
What was Benitec Biopharma’s price range in the past 12 months?
Benitec Biopharma lowest stock price was $9.85 and its highest was $17.10 in the past 12 months.
What is Benitec Biopharma’s market cap?
Benitec Biopharma’s market cap is $384.08M.
When is Benitec Biopharma’s upcoming earnings report date?
Benitec Biopharma’s upcoming earnings report date is Sep 30, 2026 which is in 107 days.
How were Benitec Biopharma’s earnings last quarter?
Benitec Biopharma released its earnings results on May 14, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.028.
Is Benitec Biopharma overvalued?
According to Wall Street analysts Benitec Biopharma’s price is currently Undervalued.
Does Benitec Biopharma pay dividends?
Benitec Biopharma pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma dividends here
What is Benitec Biopharma’s EPS estimate?
Benitec Biopharma’s EPS estimate is -0.28.
How many shares outstanding does Benitec Biopharma have?
Benitec Biopharma has 34,354,336 shares outstanding.
What happened to Benitec Biopharma’s price movement after its last earnings report?
Benitec Biopharma reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 1.717%.
Which hedge fund is a major shareholder of Benitec Biopharma?
Currently, no hedge funds are holding shares in BNTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Benitec Biopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (77.56% Upside)
$25.00 (77.56% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 76.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.77%
12-Months-Change
Fundamentals
Return on Equity
-34.82%
Trailing 12-Months
Asset Growth
77.74%
Trailing 12-Months
Company Description
Benitec Biopharma
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
BNTC Stock 12 Month Forecast
Average Price Target
$25.00
▲(77.56% Upside)
Technical Analysis
Tvardi Therapeutics
―
Assembly Biosciences
―
Rocket Pharmaceuticals
―
4D Molecular Therapeutics
―
Aura Biosciences Inc
―
Ownership Overview
5.76% Insiders
7.50% Mutual Funds
60.75% Other Institutional Investors
18.54% Public Companies and
Individual Investors